Phase Ib Study of PDR001 in Combination With Regorafenib in Adult Patients With Previously Treated Metastatic Microsatellite Stable (MSS) Colorectal Cancer
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 13 Aug 2018
At a glance
- Drugs Spartalizumab (Primary) ; Regorafenib
- Indications Adenocarcinoma; Colorectal cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors Novartis Pharmaceuticals
- 01 Aug 2018 Planned End Date changed from 31 Aug 2018 to 28 Feb 2019.
- 01 Aug 2018 Planned primary completion date changed from 31 Aug 2018 to 28 Feb 2019.
- 01 Aug 2018 Status changed from recruiting to active, no longer recruiting.